John Flack, MD
Play Button

John Flack, MD

Internist, Hypertension Specialist
Internal Medicine
Accepting new patients
Call for an appointment
217-545-8000
or
Request appointment
Language:
English

    About me

    Professional Service
    • Vice President, American Society of Hypertension (ASH) Specialist Board 2014 – present
    • Member, AHA Scientific Statement Writing Group on Resistant Hypertension 2016 – 2017
    • Member, AHA Research Strategic Outcomes Committee 2017 – present
    • Member, National Institutes of Health (NIH) Institutional Training Mechanism Review Study Section 2014 – 2018
    • Member, Psychosocial Risk and Disease Prevention Study Section, Office of Behavioral and Social sciences Diseases (NIH) 2007 – 2011
    • President, International Society on Hypertension in Blacks (ISHIB) 2001 – 2001
    • Past member, Food and Drug Administration (FDA) Cardio-renal Advisory Panel

    Editorial Boards

    • Associate Editor, American Journal of Hypertension 2016 – present
    • Associate Editor, Cardiorenal Medicine
    • Editorial Board member, Metabolic Syndrome and Drug Therapy
    • Editorial Board member, Journal of Endocrine Disorders
    • Editorial Board member, Journal of Clinical Nephrology and Research
    • Annals of Clinical and Experimental Hypertension
    • Journal of Endocrinology, Diabetes and Obesity
    • British Biotechnology Journal
    • Advances in Combination Treatments for Hypertension
    • Journal of Diabetes Research and Clinical Metabolism (JDRCM)
    • Clinical and Experimental Pharmacology and Physiology
    • Kidney and Blood Pressure Research
    • CardioRenal Medicine
    • Integrated Blood Pressure Control
    • Therapeutic Advances in Cardiovascular Disease
    • Journal of Clinical Hypertension
    • Current Cardiovascular Reports
    • Current Hypertension Reviews
    • Internal Medicine/Cardiology News

    Gender

    Male

    Education & training

    Positions
    Professor and Chair, Department of Internal Medicine
    Chair, Population Science and Policy
    Board Certifications
    Clinical Hypertension
    Internal Medicine
    Medical School
    University of Oklahoma School of Medicine, Oklahoma City, OK
    Undergraduate Degree
    Langston University, B.S., Chemistry (Math Minor),1978
    University of Oklahoma School of Public Health, MPH, 1988
    University of Minnesota School of Public Health, MPH Epidemology, 1990
    Residency
    University of Oklahoma Health Sciences Center, Oklahoma Memorial Hospital, Oklahoma City, OK
    Chief Resident, 1985-1986
    Fellowship
    Postdoctoral Research Fellow, (Cardiovascular Epidemiology) National Heart Lung and Blood Institute, 1990
    American Society of Hypertension (FASH), Fellow - 2012

    Specialties

    Conditions

    Treatments & procedures

    Patients in waiting room

    Appointments

    SIU Medicine strongly encourages all patients to verify coverage, benefits and which providers are considered in-network with their health plan. SIU Medicine has more than 300 health care providers ready to serve you and your family. SIU Medicine accepts a wide variety of governmental and non-governmental health plans to serve our community. 

    Clinical locations

    Locations

    SIU Internal Medicine Clinic

    751 N. Rutledge St. Springfield, IL 62702 1st Floor
    Get Directions
    Mon: 7:00 am-4:30 pm
    Tue: 7:00 am-7:00 pm
    Wed: 8:00 am-4:30 pm
    Thu: 7:00 am-7:00 pm
    Fri: 7:00 am-4:30 pm
    217-545-8000

    Hospital privileges

    • HSHS St. John's Hospital, Springfield, IL
    • Memorial Health, Springfield IL

    Research

    Research Interests
    Hypertension

    Clinical trials

    Trial
    Internal Medicine

    AstraZeneca BaxPA: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants with Primary Aldosteronism

    Active recruiting

    The purpose of this clinical trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals diagnosed with primary aldosteronism.

    Eligible patients include those who currently have a diagnosis of high blood pressure, specifically primary aldosteronism, despite having taken or are currently taking anti-hypertensive medications.

    Contact: Katy Martz 217-545-4342
    Trial
    Internal Medicine

    A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants with Primary Aldosteronism

    Active not recruiting
    The purpose of this study is to measure efficacy and safety with baxdrostat compared with placebo in participants with PA. The main objective is to assess the effect of treatment with baxdrostat 2 mg titrated to 4 mg versus placebo on the reduction of SBP and unsuppression of PRA in participants with PA.
    Contact: Katherine Martz 217-545-4342
    Trial
    Internal Medicine

    AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, EFFICACY, AND TOLERABILITY OF LORUNDROSTAT IN SUBJECTS WITH HYPERTENSION

    Active not recruiting
    The purpose of the study is to evaluate the long-term safety, efficacy, and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension.
    Contact: Katherine Martz 217-545-4342
    Trial
    Internal Medicine

    THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System vs. Sham for the Adjunctive Treatment of Hypertension

    Active recruiting

    The purpose of this clinical trial is to assess whether a medical device called the TIVUS System can lower high blood pressure in patients who are known to have hypertension. 

    Eligible patients include those who currently have a diagnosis of high blood pressure despite having taken or currently taking anti-hypertensive medications.

    Contact: Katy Martz 217-545-4342
    Trial
    Internal Medicine

    Radiance US GPS: The Global Paradise® System US Post Approval Study

    Active recruiting

    The purpose of this clinical study is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication.

    Eligible patients include those who currently have a diagnosis of high blood pressure despite having taken or are currently taking anti-hypertensive medications.

    Contact: Katy Martz 217-545-4342
    Trial
    Internal Medicine

    Mineralys MLS-101-301 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL ARM, MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT IN SUBJECTS WITH UNCONTROLLED AND RESISTANT HYPERTENSION

    Active not recruiting

    The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.

    Contact: Emily Starkey 217-545-7616
    Trial
    Internal Medicine

    AstraZeneca BaxHTN: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypert

    Active not recruiting

    The purpose of this clinical trial is to trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals not responding to their current treatment.

    Contact: Katy Martz 217-545-4342
    Trial
    Internal Medicine

    Mineralys (MLS-101-202): A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL ARM, MULTI-CENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT IN SUBJECTS WITH UNCONTROLLED HYPERTENSION ON A STANDARDIZED MEDICATION REGIMEN

    Active not recruiting

    The purpose of this clinical trial is to assess the blood pressure lowering effects of lorundrostat, taken once daily, in patients with high blood pressure.

    Contact: Emily Starkey 217-545-7511
    Trial
    Internal Medicine

    RADIANCE Continued Access Protocol (CAP): A study of the ReCor Medical Paradise System in Clinical Hypertension

    Active not recruiting
    The purpose of this clinical trial is to find out if a medical device called the Paradise Renal Denervation System can lower blood pressure in patients who have hypertension.
    Contact: Katy Martz 217-545-4342
    Trial
    Internal Medicine

    The "RADIANCE II" Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

    Active not recruiting
    The purpose of this clinical study is to see whether a medical device called the Paradise Renal Denervation System (also called The Paradise System) can lower high blood pressure in patients who are known to have hypertension.
    Contact: Katy Martz 217-545-4342

    Related articles

    Street in Galena, Illinois

    Summit to address rural health care workforce crisis

    With many Illinois communities struggling to find doctors, nurses and behavioral health providers, leaders in medicine, law and public policy will convene on October 15 in Springfield for the 2025 Illinois Rural and Small-Town Health Summit.
    Dr. Ruchika Goel & Dr. O.H. Wesly

    Dr. Ruchika Goel honored with endowed chair in hematologic disorders

    Dr. Ruchika Goel is the inaugural recipient of the O.H. Wesly Endowed Chair of Excellence in Hematologic Disorders. The investiture ceremony on August 26 honored both Goel’s remarkable career as a physician-scientist and the enduring legacy of Dr. Wesly, whose generosity made the endowment possible.
    Pregnant woman getting blood pressure checked with husband

    SIU research is reshaping blood pressure care

    At SIU School of Medicine, the story of hypertension research doesn’t begin in a distant lab. It begins in the clinic, often with a patient who has run out of options. A provider reviews the numbers